Abstract P1-12-11: Individualized Breast Cancer Treatment Strategies: Real-World Insights from the ROSE Study
Alessandra Fabi(Agostino Gemelli University Polyclinic), Elisabetta Munzone(Istituti di Ricovero e Cura a Carattere Scientifico), Giuseppe Capri, Luisa Carbognin(Agostino Gemelli University Polyclinic), Giulia Bianchi, M. De Laurentis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Raffaella Ruocco(University of Naples Federico II), Carmen Mocerino(Ospedale Antonio Cardarelli), Nadia Bianco(Istituti di Ricovero e Cura a Carattere Scientifico), Antonella Palazzo(Agostino Gemelli University Polyclinic), Giorgio Mauri(Fondazione IRCCS Istituto Nazionale dei Tumori), Elena Di Monte(Università Cattolica del Sacro Cuore), Valentina Frescura(Università Cattolica del Sacro Cuore), Alessandro Rossi, Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Manuelita Mazza, Ferdinando Riccardi(Ospedale Antonio Cardarelli), Valérie Perrot(Ipsen (France)), Giuseppe Fotia(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 0
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
|Clinical Cancer Research|2016|188